
## List of Publications by Year in descending order

Source: https://exaly.com/author-pdf/738874/publications.pdf Version: 2024-02-01



#	Article	IF	CITATIONS
1	Histone Deacetylase Inhibition by Sodium Butyrate Chemotherapy Ameliorates the Neurodegenerative Phenotype in Huntington's Disease Mice. Journal of Neuroscience, 2003, 23, 9418-9427.	1.7	641
2	GABA from reactive astrocytes impairs memory in mouse models of Alzheimer's disease. Nature Medicine, 2014, 20, 886-896.	15.2	577
3	Neuroprotective Effects of Phenylbutyrate in the N171-82Q Transgenic Mouse Model of Huntington's Disease. Journal of Biological Chemistry, 2005, 280, 556-563.	1.6	401
4	Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. Journal of Neurochemistry, 2005, 93, 1087-1098.	2.1	315
5	Protection from Oxidative Stress–Induced Apoptosis in Cortical Neuronal Cultures by Iron Chelators Is Associated with Enhanced DNA Binding of Hypoxia-Inducible Factor-1 and ATF-1/CREB and Increased Expression of Glycolytic Enzymes, p21 <sup>waf1/cip1</sup> , and Erythropoietin. Journal of Neuroscience, 1999, 19, 9821-9830.	1.7	312
6	Translational control of inducible nitric oxide synthase expression by arginine can explain the arginine paradox. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4843-4848.	3.3	307
7	ESET/SETDB1 gene expression and histone H3 (K9) trimethylation in Huntington's disease. Proceedings of the National Academy of Sciences of the United States of America, 2006, 103, 19176-19181.	3.3	289
8	miRâ€⊋06 regulates brainâ€derived neurotrophic factor in Alzheimer disease model. Annals of Neurology, 2012, 72, 269-277.	2.8	267
9	Transcriptional therapy with the histone deacetylase inhibitor trichostatin A ameliorates experimental autoimmune encephalomyelitis. Journal of Neuroimmunology, 2005, 164, 10-21.	1.1	266
10	Molecular Basis of Vitamin E Action. Journal of Biological Chemistry, 2003, 278, 43508-43515.	1.6	258
11	Histone deacetylase inhibitors prevent oxidative neuronal death independent of expanded polyglutamine repeats via an Sp1-dependent pathway. Proceedings of the National Academy of Sciences of the United States of America, 2003, 100, 4281-4286.	3.3	241
12	ASC is a Bax adaptor and regulates the p53–Bax mitochondrial apoptosis pathway. Nature Cell Biology, 2004, 6, 121-128.	4.6	222
13	Chronology of behavioral symptoms and neuropathological sequela in R6/2 Huntington's disease transgenic mice. Journal of Comparative Neurology, 2005, 490, 354-370.	0.9	217
14	Sp1 and Sp3 Are Oxidative Stress-Inducible, Antideath Transcription Factors in Cortical Neurons. Journal of Neuroscience, 2003, 23, 3597-3606.	1.7	210
15	Ibuprofen reduces Aβ, hyperphosphorylated tau and memory deficits in Alzheimer mice. Brain Research, 2008, 1207, 225-236.	1.1	191
16	Mitochondrial Cyclic AMP Response Element-binding Protein (CREB) Mediates Mitochondrial Gene Expression and Neuronal Survival. Journal of Biological Chemistry, 2005, 280, 40398-40401.	1.6	187
17	Chemotherapy for the Brain: The Antitumor Antibiotic Mithramycin Prolongs Survival in a Mouse Model of Huntington's Disease. Journal of Neuroscience, 2004, 24, 10335-10342.	1.7	181
18	Severe reactive astrocytes precipitate pathological hallmarks of Alzheimer's disease via H2O2â^' production. Nature Neuroscience, 2020, 23, 1555-1566.	7.1	154

#	Article	IF	CITATIONS
19	Antioxidants modulate mitochondrial PKA and increase CREB binding to D-loop DNA of the mitochondrial genome in neurons. Proceedings of the National Academy of Sciences of the United States of America, 2005, 102, 13915-13920.	3.3	145
20	SIRT3 deregulation is linked to mitochondrial dysfunction in Alzheimer's disease. Aging Cell, 2018, 17, e12679.	3.0	142
21	Modulation of lipid peroxidation and mitochondrial function improves neuropathology in Huntington's disease mice. Acta Neuropathologica, 2011, 121, 487-498.	3.9	133
22	IRE1 plays an essential role in ER stress-mediated aggregation of mutant huntingtin via the inhibition of autophagy flux. Human Molecular Genetics, 2012, 21, 101-114.	1.4	132
23	Inhibition of transglutaminase 2 mitigates transcriptional dysregulation in models of Huntington disease. EMBO Molecular Medicine, 2010, 2, 349-370.	3.3	124
24	Sequence-selective DNA binding drugs mithramycin A and chromomycin A3 are potent inhibitors of neuronal apoptosis induced by oxidative stress and DNA damage in cortical neurons. Annals of Neurology, 2001, 49, 345-354.	2.8	121
25	Dose ranging and efficacy study of high-dose coenzyme Q10 formulations in Huntington's disease mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 616-626.	1.8	119
26	Astrocytes and Microglia as Non-cell Autonomous Players in the Pathogenesis of ALS. Experimental Neurobiology, 2016, 25, 233-240.	0.7	116
27	Modulation of nucleosome dynamics in Huntington's disease. Human Molecular Genetics, 2007, 16, 1164-1175.	1.4	111
28	Combination therapy using minocycline and coenzyme Q10 in R6/2 transgenic Huntington's disease mice. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2006, 1762, 373-380.	1.8	108
29	Prosurvival and Prodeath Effects of Hypoxia-inducible Factor-1α Stabilization in a Murine Hippocampal Cell Line. Journal of Biological Chemistry, 2005, 280, 3996-4003.	1.6	98
30	MKK6 binds and regulates expression of Parkinson's diseaseâ€related protein LRRK2. Journal of Neurochemistry, 2010, 112, 1593-1604.	2.1	94
31	MST1 functions as a key modulator of neurodegeneration in a mouse model of ALS. Proceedings of the National Academy of Sciences of the United States of America, 2013, 110, 12066-12071.	3.3	84
32	Increased TRPC5 glutathionylation contributes to striatal neuron loss in Huntington's disease. Brain, 2015, 138, 3030-3047.	3.7	83
33	Epigenetic Mechanisms of Neurodegeneration in Huntington's Disease. Neurotherapeutics, 2013, 10, 664-676.	2.1	77
34	Modulation of p53 and p73 levels by cyclin G: implication of a negative feedback regulation. Oncogene, 2003, 22, 1678-1687.	2.6	72
35	Aberrant Tonic Inhibition of Dopaminergic Neuronal Activity Causes Motor Symptoms in Animal Models of Parkinson's Disease. Current Biology, 2020, 30, 276-291.e9.	1.8	69
36	Neuronal SphK1 acetylates COX2 and contributes to pathogenesis in a model of Alzheimer's Disease. Nature Communications, 2018, 9, 1479.	5.8	68

HOON RYU

#	Article	IF	CITATIONS
37	Genetic and pharmacological inactivation of the adenosine A2A receptor attenuates 3-nitropropionic acid-induced striatal damage. Journal of Neurochemistry, 2003, 88, 538-544.	2.1	65
38	The therapeutic role of creatine in Huntington's disease. , 2005, 108, 193-207.		63
39	Epigenome signatures landscaped by histone H3K9me3 are associated with the synaptic dysfunction in Alzheimer's disease. Aging Cell, 2020, 19, e13153.	3.0	53
40	Transglutaminase Activity Is Present in Highly Purified Nonsynaptosomal Mouse Brain and Liver Mitochondriaâ€. Biochemistry, 2005, 44, 7830-7843.	1.2	52
41	Role of cyclooxygenaseâ€2 induction by transcription factor Sp1 and Sp3 in neuronal oxidative and DNA damage response. FASEB Journal, 2006, 20, 2375-2377.	0.2	52
42	Increased acetylation of Peroxiredoxin1 by HDAC6 inhibition leads to recovery of AÎ <sup>2</sup> -induced impaired axonal transport. Molecular Neurodegeneration, 2017, 12, 23.	4.4	52
43	Nucleolar dysfunction in Huntington's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2014, 1842, 785-790.	1.8	50
44	Epigenetic Mechanisms of Rubinstein–Taybi Syndrome. NeuroMolecular Medicine, 2014, 16, 16-24.	1.8	49
45	Therapeutic attenuation of mitochondrial dysfunction and oxidative stress in neurotoxin models of Parkinson's disease. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2008, 1782, 151-162.	1.8	48
46	SCAMP5 Links Endoplasmic Reticulum Stress to the Accumulation of Expanded Polyglutamine Protein Aggregates via Endocytosis Inhibition. Journal of Biological Chemistry, 2009, 284, 11318-11325.	1.6	48
47	Epigenetic regulation of cholinergic receptor M1 (CHRM1) by histone H3K9me3 impairs Ca2+ signaling in Huntington's disease. Acta Neuropathologica, 2013, 125, 727-739.	3.9	48
48	KAISO, a critical regulator of p53-mediated transcription of <i>CDKN1A</i> and apoptotic genes. Proceedings of the National Academy of Sciences of the United States of America, 2014, 111, 15078-15083.	3.3	47
49	Monoallele deletion of CBP leads to pericentromeric heterochromatin condensation through ESET expression and histone H3 (K9) methylation. Human Molecular Genetics, 2008, 17, 1774-1782.	1.4	44
50	EWSR1, a multifunctional protein, regulates cellular function and aging via genetic and epigenetic pathways. Biochimica Et Biophysica Acta - Molecular Basis of Disease, 2019, 1865, 1938-1945.	1.8	44
51	Mitochondrial nuclear receptors and transcription factors: Who's minding the cell?. Journal of Neuroscience Research, 2008, 86, 961-971.	1.3	43
52	Transcriptome analyses of chronic traumatic encephalopathy show alterations in protein phosphatase expression associated with tauopathy. Experimental and Molecular Medicine, 2017, 49, e333-e333.	3.2	41
53	A Difluoroboron β-Diketonate Probe Shows "Turn-on―Near-Infrared Fluorescence Specific for Tau Fibrils. ACS Chemical Neuroscience, 2017, 8, 2124-2131.	1.7	41
54	The failure of mitochondria leads to neurodegeneration: Do mitochondria need a jump start?â~†. Advanced Drug Delivery Reviews, 2009, 61, 1316-1323.	6.6	40

#	Article	IF	CITATIONS
55	A Smart Near-Infrared Fluorescence Probe for Selective Detection of Tau Fibrils in Alzheimer's Disease. ACS Chemical Neuroscience, 2016, 7, 1474-1481.	1.7	40
56	Associations between brain inflammatory profiles and human neuropathology are altered based on apolipoprotein E ε4 genotype. Scientific Reports, 2020, 10, 2924.	1.6	40
57	Brain injury induces HIF-1α-dependent transcriptional activation of LRRK2 that exacerbates brain damage. Cell Death and Disease, 2018, 9, 1125.	2.7	39
58	Astrocytic proBDNF and Tonic GABA Distinguish Active versus Reactive Astrocytes in Hippocampus. Experimental Neurobiology, 2018, 27, 155-170.	0.7	39
59	Activation of Etsâ€2 by oxidative stress induces Bclâ€xL expression and accounts for glial survival in amyotrophic lateral sclerosis. FASEB Journal, 2009, 23, 1739-1749.	0.2	37
60	Thrombospondin-1 prevents amyloid beta–mediated synaptic pathology in Alzheimer's disease. Neurobiology of Aging, 2015, 36, 3214-3227.	1.5	37
61	Epigenetic modification is linked to Alzheimer's disease: is it a maker or a marker?. BMB Reports, 2010, 43, 649-655.	1.1	37
62	Motor neuronal protection by l-arginine prolongs survival of mutant SOD1 (G93A) ALS mice. Biochemical and Biophysical Research Communications, 2009, 384, 524-529.	1.0	36
63	Increased stem cell proliferation in the spinal cord of adult amyotrophic lateral sclerosis transgenic mice. Journal of Neurochemistry, 2007, 102, 1125-1138.	2.1	31
64	Deregulation of BRCA1 Leads to Impaired Spatiotemporal Dynamics of γ-H2AX and DNA Damage Responses in Huntington's Disease. Molecular Neurobiology, 2012, 45, 550-563.	1.9	31
65	Differential regulation of neuronal and inducible nitric oxide synthase (NOS) in the spinal cord of mutant SOD1 (G93A) ALS mice. Biochemical and Biophysical Research Communications, 2009, 387, 202-206.	1.0	30
66	UBE4B, a microRNA-9 target gene, promotes autophagy-mediated Tau degradation. Nature Communications, 2021, 12, 3291.	5.8	30
67	Astrocytes Render Memory Flexible by Releasing D-Serine and Regulating NMDA Receptor Tone in the Hippocampus. Biological Psychiatry, 2022, 91, 740-752.	0.7	30
68	Expression of Taurine Transporter (TauT) is Modulated by Heat Shock Factor 1 (HSF1) in Motor Neurons of ALS. Molecular Neurobiology, 2013, 47, 699-710.	1.9	29
69	Differential expression of c-Ret in motor neurons versus non-neuronal cells is linked to the pathogenesis of ALS. Laboratory Investigation, 2011, 91, 342-352.	1.7	28
70	"Turn-On―Quinoline-Based Fluorescent Probe for Selective Imaging of Tau Aggregates in Alzheimer's Disease: Rational Design, Synthesis, and Molecular Docking. ACS Sensors, 2021, 6, 2281-2289.	4.0	28
71	ESET methylates UBF at K232/254 and regulates nucleolar heterochromatin plasticity and rDNA transcription. Nucleic Acids Research, 2014, 42, 1628-1643.	6.5	26
72	Metabolomic Analysis Identifies Alterations of Amino Acid Metabolome Signatures in the Postmortem Brain of Alzheimer's Disease. Experimental Neurobiology, 2019, 28, 376-389.	0.7	26

#	Article	IF	CITATIONS
73	Norepinephrine Deficiency Is Caused by Combined Abnormal mRNA Processing and Defective Protein Trafficking of Dopamine β-Hydroxylase. Journal of Biological Chemistry, 2011, 286, 9196-9204.	1.6	25
74	Gamma subunit of complement component 8 is a neuroinflammation inhibitor. Brain, 2021, 144, 528-552.	3.7	25
75	Emerging chemotherapeutic strategies for Huntington's disease. Expert Opinion on Emerging Drugs, 2005, 10, 345-363.	1.0	24
76	<i>Uvrag</i> targeting by <i>Mir125a</i> and <i>Mir351</i> modulates autophagy associated with <i>Ewsr1</i> deficiency. Autophagy, 2015, 11, 796-811.	4.3	24
77	Omi is a mammalian heat-shock protein that selectively binds and detoxifies oligomeric amyloid-β. Journal of Cell Science, 2009, 122, 1917-1926.	1.2	23
78	Remodeling of heterochromatin structure slows neuropathological progression and prolongs survival in an animal model of Huntington's disease. Acta Neuropathologica, 2017, 134, 729-748.	3.9	23
79	Altered Synaptic Vesicle Release and Ca2+ Influx at Single Presynaptic Terminals of Cortical Neurons in a Knock-in Mouse Model of Huntington's Disease. Frontiers in Molecular Neuroscience, 2018, 11, 478.	1.4	23
80	Visualization of soluble tau oligomers in TauP301L-BiFC transgenic mice demonstrates the progression of tauopathy. Progress in Neurobiology, 2020, 187, 101782.	2.8	22
81	[16] In vitro model of oxidative stress in cortical neurons. Methods in Enzymology, 2002, 352, 183-190.	0.4	19
82	Power Failure of Mitochondria and Oxidative Stress in Neurodegeneration and Its Computational Models. Antioxidants, 2021, 10, 229.	2.2	17
83	Translational Therapeutic Str ategies in Amyotrophic Lateral Sclerosis. Mini-Reviews in Medicinal Chemistry, 2007, 7, 141-150.	1.1	16
84	Distinct dual roles of p-Tyr42 RhoA GTPase in tau phosphorylation and ATP citrate lyase activation upon different AÎ <sup>2</sup> concentrations. Redox Biology, 2020, 32, 101446.	3.9	16
85	The alteration of serine transporter activity in a cell line model of amyotrophic lateral sclerosis (ALS). Biochemical and Biophysical Research Communications, 2017, 483, 135-141.	1.0	14
86	Pathogenic Genome Signatures That Damage Motor Neurons in Amyotrophic Lateral Sclerosis. Cells, 2020, 9, 2687.	1.8	14
87	Alterations of transcriptome signatures in head trauma-related neurodegenerative disorders. Scientific Reports, 2020, 10, 8811.	1.6	14
88	L-Citrulline Level and Transporter Activity Are Altered in Experimental Models of Amyotrophic Lateral Sclerosis. Molecular Neurobiology, 2021, 58, 647-657.	1.9	13
89	AÎ <sup>2</sup> modulates actin cytoskeleton via SHIP2-mediated phosphoinositide metabolism. Scientific Reports, 2019, 9, 15557.	1.6	12
90	In silico probing and biological evaluation of SETDB1/ESET-targeted novel compounds that reduce tri-methylated histone H3K9 (H3K9me3) level. Journal of Computer-Aided Molecular Design, 2017, 31, 877-889.	1.3	10

#	Article	IF	CITATIONS
91	Genetic Ablation of EWS RNA Binding Protein 1 (EWSR1) Leads to Neuroanatomical Changes and Motor Dysfunction in Mice. Experimental Neurobiology, 2018, 27, 103-111.	0.7	10
92	Decoding the temporal nature of brain GR activity in the NFήB signal transition leading to depressive-like behavior. Molecular Psychiatry, 2021, 26, 5087-5096.	4.1	10
93	Post-Translational Modification of Human Histone by Wide Tolerance of Acetylation. Cells, 2017, 6, 34.	1.8	9
94	Quantitative Proteomic Analysis Reveals Impaired Axonal Guidance Signaling in Human Postmortem Brain Tissues of Chronic Traumatic Encephalopathy. Experimental Neurobiology, 2019, 28, 362-375.	0.7	9
95	Conditional Knockout of Cav2.1 Disrupts the Accuracy of Spatial Recognition of CA1 Place Cells and Spatial/Contextual Recognition Behavior. Frontiers in Behavioral Neuroscience, 2016, 10, 214.	1.0	8
96	Neuroanatomical Visualization of the Impaired Striatal Connectivity in Huntington's Disease Mouse Model. Molecular Neurobiology, 2016, 53, 2276-2286.	1.9	8
97	Acceleration of somatic cell reprogramming into the induced pluripotent stem cell using a mycosporine-like amino acid, Porphyra 334. Scientific Reports, 2020, 10, 3684.	1.6	8
98	Hevin–calcyon interaction promotes synaptic reorganization after brain injury. Cell Death and Differentiation, 2021, 28, 2571-2588.	5.0	8
99	Dysfunction of X-linked inhibitor of apoptosis protein (XIAP) triggers neuropathological processes via altered p53 activity in Huntington's disease. Progress in Neurobiology, 2021, 204, 102110.	2.8	8
100	Hypermethylation of Mest promoter causes aberrant Wnt signaling in patients with Alzheimer's disease. Scientific Reports, 2021, 11, 20075.	1.6	8
101	Neuroinflammation Induced by Transgenic Expression of Lipocalin-2 in Astrocytes. Frontiers in Cellular Neuroscience, 2022, 16, 839118.	1.8	8
102	How Microglia Manages Non-cell Autonomous Vicious Cycling of AÎ <sup>2</sup> Toxicity in the Pathogenesis of AD. Frontiers in Molecular Neuroscience, 2020, 13, 593724.	1.4	7
103	Modulation of SETDB1 activity by APQ ameliorates heterochromatin condensation, motor function, and neuropathology in a Huntington's disease mouse model. Journal of Enzyme Inhibition and Medicinal Chemistry, 2021, 36, 856-868.	2.5	7
104	Modulation of autophagy by miRNAs. BMB Reports, 2015, 48, 371-372.	1.1	7
105	The Alteration of L-Carnitine Transport and Pretreatment Effect under Glutamate Cytotoxicity on Motor Neuron-Like NSC-34 Lines. Pharmaceutics, 2021, 13, 551.	2.0	6
106	Non-Cell Autonomous and Epigenetic Mechanisms of Huntington's Disease. International Journal of Molecular Sciences, 2021, 22, 12499.	1.8	6
107	Monocarboxylate transporter functions and neuroprotective effects of valproic acid in experimental models of amyotrophic lateral sclerosis. Journal of Biomedical Science, 2022, 29, 2.	2.6	6
108	Dysfunction of striatal MeCP2 is associated with cognitive decline in a mouse model of Alzheimer's disease. Theranostics, 2022, 12, 1404-1418.	4.6	5

#	Article	IF	CITATIONS
109	Integrated analysis of omics data using microRNA-target mRNA network and PPI network reveals regulation of Gnai1 function in the spinal cord of Ews/Ewsr1 KO mice. BMC Medical Genomics, 2016, 9, 33.	0.7	4
110	The Function of Glial Cells in the Neuroinflammatory and Neuroimmunological Responses. Cells, 2022, 11, 659.	1.8	4
111	Sodium phenylbutyrate prolongs survival and regulates expression of anti-apoptotic genes in transgenic amyotrophic lateral sclerosis mice. Journal of Neurochemistry, 2006, 96, 908-908.	2.1	2
112	Increases of Phosphorylated Tau (Ser202/Thr205) in the Olfactory Regions Are Associated with Impaired EEG and Olfactory Behavior in Traumatic Brain Injury Mice. Biomedicines, 2022, 10, 865.	1.4	2
113	Non-Targeted Metabolomics Approach Revealed Significant Changes in Metabolic Pathways in Patients with Chronic Traumatic Encephalopathy. Biomedicines, 2022, 10, 1718.	1.4	2